[2]Aribi, M. (2020). Introductory Chapter: B-Cells. IntechOpen. doi: 10.5772/intechopen.90636 [3]Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M. Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci U S A. 2006 Sep 12...
Mb1Cre/+ mice developed T-ALL/T-lymphoblastic lymphoma (LLy), with a median latency to death of 97 days and near-complete penetrance. The disease demonstrated variable infiltration of the bone marrow, spleen, and thymus, and displayed an aberrant CD4+CD8+CD44+CD25+/− immunophenotype. The ...
To address this possibility, we first generated KrasG12Dtransgenic mice with T-cell-specific expression of the pan-Notch inhibitor, dominant-negative Mastermind (DNMAML). These mice developed leukemia, but instead of accessing alternative oncogenic pathways, the tumor cells acquired Notch1 mutations ...
[3]Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M. Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13789-94. doi: 10.1073/pnas.0605944103....
E2A-HLF/Mb1.Cre transgenic mice develop myeloproliferative-like disease.Jesús, DuqueAfonsoKevin, S. SmithMichael, L. Cleary